期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
两种药物治疗乙肝肝硬化的疗效及其对肝纤维化程度、炎症反应及免疫相关指标的影响 被引量:4
1
作者 孙波 叶丽红 +1 位作者 吴婷婷 罗酩 《世界华人消化杂志》 CAS 2018年第35期2064-2070,共7页
目的探讨茵芪肝复颗粒联合恩替卡韦治疗乙肝肝硬化的疗效及其对肝纤维化程度、炎症反应及免疫相关指标的影响。方法选取浙江省中西医结合医院自2016-04/2017-04期间收治的86例慢性乙型肝炎肝硬化患者作为观察对象,按照随机数表法分为对... 目的探讨茵芪肝复颗粒联合恩替卡韦治疗乙肝肝硬化的疗效及其对肝纤维化程度、炎症反应及免疫相关指标的影响。方法选取浙江省中西医结合医院自2016-04/2017-04期间收治的86例慢性乙型肝炎肝硬化患者作为观察对象,按照随机数表法分为对照组、研究组,分别43例。对照组给予恩替卡韦治疗,研究组给予茵芪肝复颗粒联合恩替卡韦治疗,对比两组中医证候积分、肝脏超声、肝纤维化指标、炎症反应指标、免疫功能指标的变化。结果治疗后,两组患者的中医证候积分、脾脏厚度均显著低于治疗前(P<0.05)。且观察组治疗后中医证候积分、脾脏厚度显著低于对照组同期(P<0.05)。治疗后,两组ALB水平均高于治疗前(P<0.05),其中,研究组治疗后显著高于对照组同期(P<0.05)。治疗前,两组肝纤维化指标采用酶联免疫法测定层黏连蛋白(laminin,LN)、透明质酸(hyaluronic acid, HA)、Ⅳ型胶原(typeⅣcollagen,Ⅳ-C)和Ⅲ型前胶原(typeⅢprocollagen,PC-Ⅲ)比较差异无统计学意义(P>0.05)。治疗后,两组LN、HA、Ⅳ-C和PC-Ⅲ均显著低于治疗前(P<0.05)。且研究组治疗后LN、HA、Ⅳ-C和PC-Ⅲ均低于对照组同期(P<0.05)。治疗前,两组免疫指标CD_3^+、CD_4^+、CD_8^+指标比较差异无统计学意义(P>0.05)。治疗后,两组CD_3^+、CD_4^+水平均高于治疗, CD_8^+低于治疗前(P<0.05)。其中,研究组治疗后CD_3^+、CD_4^+均高于对照组同期, CD_8^+低于对照组同期,比较差异有统计学意义(P<0.05)。治疗前,两组炎症反应指标IL-15、IL-16、TGF-β1比较差异无统计学意义(P>0.05)。治疗后,两组IL-15、IL-16、TGF-β1水平显著低于治疗前(P<0.05)。且研究组治疗后IL-15、IL-16、TGF-β1水平均低于对照组(P<0.05)。治疗后两组肝纤维化程度分级均改善,研究组自身比较(P<0.05),对照组自身比较(P<0.05),治疗后两组比较差异不明显(P>0.05)。结论茵芪肝复颗粒联合恩替卡韦治疗可延缓慢性乙型肝炎后肝纤维化进程,减轻炎症反应,提高患者的免疫功能,具有较高推广应用价值。 展开更多
关键词 茵芪肝复颗粒 恩替卡韦 慢性乙型肝炎 肝纤维化 炎症反应 免疫功能
下载PDF
Hepatitis B virus X protein accelerates the development of hepatoma 被引量:26
2
作者 Xiao-Dong Zhang Yuan Wang li-hong ye 《Cancer Biology & Medicine》 SCIE CAS CSCD 2014年第3期182-190,共9页
The chronic infection of hepatitis B virus(HBV) is closely related to the occurrence and development of hepatocellular carcinoma(HCC). Accumulated evidence has shown that HBV X protein(HBx protein) is a multifunctiona... The chronic infection of hepatitis B virus(HBV) is closely related to the occurrence and development of hepatocellular carcinoma(HCC). Accumulated evidence has shown that HBV X protein(HBx protein) is a multifunctional regulator with a crucial role in hepatocarcinogenesis. However, information on the mechanism by which HBV induces HCC is lacking. This review focuses on the pathological functions of HBx in HBV-induced hepatocarcinogenesis. As a transactivator, HBx can modulate nuclear factor kappa-light-chain-enhancer of activated B cells(NF-κB) and transcription factor AP-2. Moreover, HBx can affect regulatory non-coding RNAs(ncRNAs) including microRNAs and long ncRNAs(lncRNAs), such as miRNA-205 and highly upregulated in liver cancer(HULC), respectively. HBx is also involved in epigenetic modification, including methylation and acetylation. HBx interacts with various signal-transduction pathways, such as protein kinase B/Akt, Wnt/β-catenin, signal transducer and activator of transcription, and NF-κB pathways. Moreover, HBx affects cellular fate by shifting the balance toward cell survival. HBx may lead to the loss of apoptotic functions or directly contributes to oncogenesis by achieving transforming functions, which induce hepatocarcinogenesis. Additionally, HBx can modulate apoptosis and immune response by direct or indirect interaction with host factors. We conclude that HBx hastens the development of hepatoma. 展开更多
关键词 Hepatocellular carcinoma(HCC) hepatitis B virus(HBV) HBV X protein(HBx protein) hepatocarcinogenesis
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部